Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28423002 | 0.83 | KMT2A (0.39) | KMT2AHTTSLC1A1TSHRMAPT | |
| SCHEMBL7627184 | 0.82 | TSHR (0.50) | KMT2AHTTSLC1A1TSHRCA1 | |
| SCHEMBL5228321 | 0.82 | TSHR (0.50) | KMT2AHTTSLC1A1TSHRCA1 | |
| SCHEMBL121000 | 0.82 | TSHR (0.50) | KMT2AHTTSLC1A1TSHRCA1 | |
| SCHEMBL12744032 | 0.81 | TSHR (0.56) | KMT2AHTTSLC1A1TSHRNPC1 | |
| SCHEMBL13405408 | 0.80 | KMT2A (0.58) | KMT2AHTTSLC1A1TSHRNPC1 | |
| SCHEMBL3374459 | 0.79 | HTT (0.46) | KMT2AHTTSLC1A1TSHRNPC1 | |
| SCHEMBL2308784 | 0.79 | HTT (0.46) | KMT2AHTTSLC1A1TSHRNPC1 | |
| SCHEMBL3080039 | 0.78 | TSHR (0.48) | KMT2AHTTSLC1A1TSHRNPC1 | |
| SCHEMBL28589416 | 0.76 | HTT (0.49) | KMT2AHTTSLC1A1TSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |